Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
KOREA E & EX
Advantech Europe

New Injection Device Approved for Methotrexate

By HospiMedica International staff writers
Posted on 31 Oct 2013
Image: The Otrexup self-injector in 10 mg formulation (Photo courtesy of Antares Pharma).
Image: The Otrexup self-injector in 10 mg formulation (Photo courtesy of Antares Pharma).
A self-injection device for the subcutaneous administration of methotrexate (MTX) facilitates drug delivery for arthritis sufferers.

The Otrexup self-injector is intended for use by adults with active, severe rheumatoid arthritis (RA) or psoriasis who have not responded to or been able to tolerate first line therapy, as well as for children with active polyarticular juvenile idiopathic arthritis. The device is not indicated for use in children with psoriasis, nor should it be used by pregnant women. And while MTX is also used in the treatment of cancer, Otrexup is not indicated for that use.

Methotrexate is considered a disease-modifying antirheumatic drug (DMARD), effective in relieving joint inflammation and pain, slowing disease progression, and preventing disability by delaying joint destruction. People with RA may be more likely to continue treatment with MTX than with other DMARDs, with more than 50% of people who take MTX for RA continuing to take the medicine for more than three years, longer than any other DMARD. The Otrexup self-injector is a product of Antares Pharma (Ewing, NJ, USA), and has been approved by the US Food and Drug Administration (FDA).

“We are very pleased to receive approval from the FDA for Otrexup because we believe it is an important step up in the standard of care for people living with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis,” said Paul Wotton, PhD, president and CEO of Antares Pharma.

“The availability of an easy and safe way to administer subcutaneous methotrexate may overcome some of the current barriers to parenteral administration, which could enable more patients to realize the possibility of continued disease control and therefore benefit from subcutaneous methotrexate,” commented Michael Schiff, MD, of the University of Colorado (Denver, USA).

MTX is a cornerstone of therapy for RA and psoriasis, usually given orally once a week, but a substantial number of patients do not respond adequately or cannot tolerate the side effects of the drug, such as nausea, abdominal pain, and dyspepsia. Those patients can be given methotrexate with subcutaneous injections, which can increase the drug's bioavailability, but injection can also pose problems for patients who are afraid of needles or do not have enough manual dexterity remaining to manage needles, syringes, and vials.

Related Links:

Antares Pharma



Channels

Surgical Techniques

view channel

Nonlinear Acoustic Analysis Could Help Destroy Kidney Stones

Mathematical analysis and simulation of models governing the propagation of sound in fluids could enhance lithotripsy, according to a new study. Researchers at Alpen-Adria-Universität (Klagenfurt am Wörthersee, Austria) are developing an application-oriented comprehensive mathematical analysis of the underlying model... Read more

Women's Health

view channel

Nitrous Oxide for Labor Makes US Comeback

Long used for its anxiolytic properties during labor in European countries and Canada, nitrous oxide (N2O) use is resurging in the United States. While in countries such as Norway, New Zealand, Sweden, Australia, and England, usage rates of inhalational N2O during parturition reach 70%, it has only recently become an... Read more

Health IT

view channel
Image: ResolutionMD across multiple devices (Photo courtesy of Calgary Scientific).

Healthcare Communication Platform Offers Seamless Image Access

Novel diagnostic medical imaging software offers better access to health information, supports increased teamwork, and enhances communication among practitioners and patients. ResolutionMD enables doctors... Read more

Business

view channel

Pfizer to Buy Hospira to Bolster Hospital Products

Pfizer (New York, NY, USA) has entered into a definitive merger agreement with Hospira (Lake Forest, IL, USA), in a move designed to significantly enhance their global established pharmaceutical (GEP) business, for a total enterprise value of approximately USD 17 billion. The strategic complementary combination will... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.